Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock.

A number of other equities research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, March 4th. Lake Street Capital decreased their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th.

Ekso Bionics Price Performance

Shares of NASDAQ:EKSO opened at $0.44 on Thursday. The business’s 50 day simple moving average is $0.52 and its 200-day simple moving average is $0.74. The firm has a market capitalization of $10.85 million, a price-to-earnings ratio of -0.67 and a beta of 1.43. Ekso Bionics has a 12 month low of $0.34 and a 12 month high of $1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. As a group, equities analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.